Clindamycin: a review of fifteen years of experience.

Reviews of infectious diseases ·Vol. 4 ·No. 6 ·1982-00-00 ·Pages 1133-53

Dhawan VK, Thadepalli H

Abstract

Clindamycin, the 7(S)-chloro-7-deoxy derivative of lincomycin, has stood the test of time in the treatment of anaerobic infections. Clindamycin inhibits protein synthesis by acting on the 50S ribosomal subunits of bacteria. The colitis resulting from the use of clindamycin has been extensively studied and is now easily manageable. Although newer antibiotics active against anaerobes are available, clindamycin remains a reliable and well-tested antibiotic for use in anaerobic infections.

MeSH Terms

Animals Bacteroides Infections/drug therapy Clindamycin/metabolism,pharmacology,therapeutic use Clostridium/growth & development Cricetinae Drug Synergism Escherichia coli Infections/drug therapy Gentamicins/pharmacology,therapeutic use Gram-Negative Aerobic Bacteria/growth & development Gram-Negative Anaerobic Bacteria/growth & development Guinea Pigs Haplorhini Humans Kinetics Malaria/drug therapy Mice Microbial Sensitivity Tests Peptococcus/growth & development Rabbits Staphylococcal Infections/drug therapy Staphylococcus/growth & development Streptococcus/growth & development

Chemicals

Gentamicins Clindamycin

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Dhawan V K

Thadepalli H

Article Info

Journal

Reviews of infectious diseases

Abbr.

Rev Infect Dis

ISSN

0162-0886

DOI

10.1093/clinids/4.6.1133

Published

1982-00-00

Pages

1133-53

Language

English

Region

United States

NLM ID

7905878

Subset

External Links

PubMed source DOI: 10.1093/clinids/4.6.1133

Analysis Services

Clindamycin: a review of fifteen years of experience.

Contact

WeChat Official Account